Onconetix Reports 83.9% Revenue Decline in Q2 2026, Faces Financial Challenges

Onconetix, Inc. reported a significant decline in financial performance for the second quarter of 2026, with revenues dropping to $17,120, an 83.9% decrease from $106,494 in the same period last year. For the first half of 2026, total revenue was $38,577, down 81.5% from $208,124 in the first half of 2025. The company attributed this decline primarily to reduced customer demand and timing of orders for its diagnostic product, Proclarix, which is designed for prostate cancer diagnosis. The gross profit for the second quarter fell to $4,303, compared to $70,503 in the prior year, reflecting a gross margin decrease from 66.2% to 25.1%.

Operating expenses increased during the quarter, with selling, general, and administrative expenses rising by 47.4% to $2,245,653, largely due to higher professional fees associated with regulatory and legal matters. Research and development expenses also saw a notable increase, reflecting new clinical study agreements. The company recorded an impairment of goodwill of $486,000 for the quarter, down from $594,000 in the previous year. Overall, Onconetix reported a net loss of $2,867,303 for the quarter, compared to a loss of $2,372,442 in the same period last year.

In terms of operational developments, Onconetix has made strategic moves to enhance its market position. The company completed the acquisition of Proteomedix AG in December 2023, which brought Proclarix under its portfolio. Additionally, Onconetix has initiated a multi-center clinical validation study, known as the PRIME study, in collaboration with LabCorp to evaluate Proclarix in the U.S. market. The company is also focusing on expanding its commercialization efforts for Proclarix, which is already CE-marked and available in Europe.

As of June 30, 2026, Onconetix had cash reserves of approximately $5.9 million, with a working capital surplus of about $3.6 million. However, the company continues to face substantial operating losses, with an accumulated deficit of approximately $138.3 million. The management has expressed concerns regarding the company's ability to continue as a going concern, emphasizing the need for additional capital to fund operations and support strategic initiatives. In July 2026, Onconetix entered into a securities purchase agreement for Series F Preferred Stock, which is expected to provide approximately $30.2 million in gross proceeds, aimed at bolstering its liquidity position.

Looking ahead, Onconetix plans to focus on the commercialization of Proclarix and is actively seeking additional funding through equity or debt financing. The company remains committed to its strategic initiatives, including the proposed acquisition of Realbotix, although it acknowledges the challenges posed by its current financial situation and the need for sustained revenue generation to support its operations.